What is the survival rate for a second recurrence of high-grade serous endometrial cancer with P53, pMMR, and triple-negative biomarkers?
This is a really important question, and it's completely understandable to want clear information given everything that's been faced so far. The honest answer is that survival rates for Show Full Answer
What is the survival rate for a second recurrence of high-grade serous endometrial cancer with P53, pMMR, and triple-negative biomarkers?
This is a really important question, and it's completely understandable to want clear information given everything that's been faced so far. The honest answer is that survival rates for a second recurrence in this situation are difficult to pin down to a single number — they vary significantly based on where the cancer has returned, overall health, and what treatments are still available.
Here's what is generally known about recurrent endometrial cancer survival:
- For recurrent or advanced endometrial cancer overall, median survival is around 12 to 15 months
- If cancer returns in the pelvis, the 3-year survival rate is approximately 73.4%
- If cancer has spread to other parts of the body (like the lungs), the 3-year survival rate drops to around 38.1% High-grade serous endometrial cancer is a Type 2 cancer, which tends to be more aggressive, and studies show around 50% of Type 2 cases recur. A pMMR status also means immunotherapy like pembrolizumab alone is less likely to be effective, which makes treatment more challenging.
The five-year survival rate for stage 3 or 4 serous endometrial cancer is around 33%, though this is a general figure and doesn't reflect individual circumstances. Given the complexity of this specific situation — triple-negative biomarkers, pMMR status, and a second recurrence — it's really worth having an urgent, detailed conversation with an oncologist about:
- Clinical trials, which may offer access to newer treatments not yet widely available
- Targeted therapies such as lenvatinib combined with pembrolizumab, or bevacizumab
- Alternative chemotherapy agents like cisplatin, docetaxel, or doxorubicin
Clinical trials in particular are showing promising results for people with recurrent endometrial cancer, especially for cases that are harder to treat with standard options. Asking for a referral to a specialist cancer center could open up more possibilities.
June 15
Join
Your Privacy Choices
